ABSTRACT
ABSTRACT: Conventional therapies for CD8 + cutaneous T-cell lymphoma include topical steroids, topical nitrogen mustard, topical bexarotene, ultraviolet B therapy, psoralen and ultraviolet A therapy, local radiotherapy, and interferon alfa; however, these treatments are often found to be ineffective. Presented is a case of CD8 + cutaneous T-cell lymphoma with near-complete response to narrow-band ultraviolet therapy because of chronic radiation dermatitis initially believed to be possible progression of a CD8 + cutaneous epidermotropic cytotoxic T-cell lymphoma.
Subject(s)
Antineoplastic Agents , Dermatitis , Lymphoma, T-Cell, Cutaneous , Skin Neoplasms , Ultraviolet Therapy , Humans , Lymphoma, T-Cell, Cutaneous/pathology , Skin Neoplasms/pathology , Antineoplastic Agents/therapeutic use , Ultraviolet Therapy/adverse effects , CD8-Positive T-Lymphocytes/pathology , Dermatitis/pathologyABSTRACT
Calcipotriol (calcipotriene) is a synthetic vitamin D3 derivative that is a standard treatment option for psoriasis. It is generally well tolerated with minimal side effects. Due to its ability to reduce keratinocyte proliferation and induce keratinocyte differentiation as well as its immunomodulatory effects, calcipotriol has been used to treat a variety of skin disorders such as atopic dermatitis, actinic keratoses, lichen planus, seborrheic keratoses, and vitiligo [1]. We surveyed the literature examining the use of calcipotriol for non-psoriatic dermatologic disease.
